# SyMap

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/symap

- Industry: Medical Devices & Equipment
- Headquarters: Suzhou, China
- Website: www.symapmedical.net
- Total disclosed funding: $135M
- Latest round: Series E (Dec 1, 2021)
- Investors on record: 11

## About

Based in Suzhou, China and established in 2012, SyMap is a medical equipment developer that focuses on developing ablation catheter and supporting frequency ablation instrument for the treatment of hypertension and related cardiovascular diseases. The company founder is Jie Wang, who served as Dean of School of Medicine of Nanjing University, Executive Vice Dean of Research Institute of Jiangsu Provincial School of Clinical Medicine.  In 2014, it obtained the NMPA medical device production enterprise license. In 2020, the company's hypertension/asthma clinical trials progressed in phases. The bronchial radiofrequency ablation system passed the NMPA special approval application for innovative medical devices.

The company developed two products, renal nerve ablation system for hypertension, and bronchial radiofrequency ablation system for severe asthma. Theses products are carrying out clinical registration trials, and have entered National Medical Products Administration (NMPA ) special review process for innovative medical devices.

## Funding rounds

- Series E, Dec 1, 2021, $100M — Hong Shan, Primavera Capital Group, VMS Asset Management, Simiao Capital
- Series D, Apr 19, 2021 — Simiao Capital
- Series D, Dec 22, 2020, $15M — Puhua Capital, Jisu Capital, Zheshang Group
- Series C, Nov 12, 2018, $10M — Kington Capital, Ming Bioventures
- Series B, Aug 22, 2015, $10M — Hong Shan, SB China Venture Capital
- Series A, Mar 18, 2014 — SB China Venture Capital, Oriza Holdings

## Investors

- SB China Venture Capital (https://capitalatlas.ai/funds/sb-china-venture-capital) — Series A, Series B
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A
- Hong Shan — Series B, Series E
- Kington Capital (https://capitalatlas.ai/funds/kington-capital) — Series C
- Ming Bioventures (https://capitalatlas.ai/funds/ming-bioventures) — Series C
- Puhua Capital (https://capitalatlas.ai/funds/puhua-capital) — Series D
- Jisu Capital (https://capitalatlas.ai/funds/jisu-capital) — Series D
- Zheshang Group (https://capitalatlas.ai/funds/zheshang-group) — Series D
- Simiao Capital (https://capitalatlas.ai/funds/simiao-capital) — Series D, Series E
- Primavera Capital Group (https://capitalatlas.ai/funds/primavera-capital-group) — Series E
- VMS Asset Management (https://capitalatlas.ai/funds/vms-asset-management) — Series E